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Background: To evaluate the association between the genetic polymorphism of the solute carrier organic anion
transporter family member 1B1 (SLCO1B1, also known as organic anion transport polypeptide C) and
hyperbilirubinemia in Chinese neonates.
Methods: 183 infants with hyperbilirubinemia and 192 control subjects from the Fifth People’s Hospital of
Shenzhen were recruited. Polymerase chain reaction, restriction fragment length polymorphisms and agarose gel
electrophoresis techniques were used to detect genetic variants of SLCO1B1.
Results: The study revealed that SLCO1B1 388 G > A occurred significantly more frequently in neonates with
hyperbilirubinemia than in controls (RR = 1.50; 95% CI: 1.13–2.00). There were no significant differences in SLCO1B1
521 T > C between the hyperbilirubinemia and the control group (RR, 1.00; 95% CI, 0.72–1.40). No carriage of the
C to A substitution at nucleotide 463 was detected.
Conclusion: The SLCO1B1 388 G > A variant is associated with neonatal hyperbilirubinemia in Chinese neonates.
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Neonatal hyperbilirubinemia is one of the most common
problems encountered in newborns, occurring in up to
60% of healthy full-term and 80% of preterm newborns
during the first week of life [1]. Most cases are physio-
logical and do not result in serious consequences, but
systematic failure to identify at-risk infants has been
associated with an increased risk of severe hyperbilirubi-
nemia, which is one of the reasons for the higher
incidence of kernicterus, and may result in neurodeve-
lopmental abnormalities such as hearing loss, athetosis,
and rarely, intellectual deficits [2].
Bilirubin, the hydrophobic end product of heme
degradation, is metabolized in the hepatocyte to hydro-
philic conjugates, which are then efficiently eliminated
in the bile [3]. Following uptake from the plasma,
unconjugated bilirubin is transported from the blood
circulation to the liver by organic anion transporter
polypeptide 2 (OATP2), also known as OATP-C and
LST1, which is an uptake transporter located on the* Correspondence: jiebol@126.com
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reproduction in any medium, provided the orbasolateral (sinusoidal) membrane of human hepato-
cytes, encoded by the gene of the solute carrier organic
anion transporter family member 1B1 (SLCO1B1) [4].
At this point, OATP1B1 is conjugated with glucuronic
acid and bilirubin in the endoplasmic reticulum through
a catalytic reaction involving UDP-glucuronosyltransferase
1A1 (UGT1A1), which results in conjugated bilirubin, also
known as water-soluble bilirubin. The conjugated bilirubin
glucuronides are excreted in the bile, pass through the
intestine, and are deconjugated by bacteria that reduce
some of the bilirubin to urobilinogens. Approximately
80% of the urobilinogens are excreted in the stool and
the remainder is either reabsorbed into the entero-
hepatic circulation or goes to the kidneys to be excreted
in urine [3]. Thus, OATP1B1 or UGT1A1 are respon-
sible for bilirubin conjugation, and it follows that a de-
fect in the function of either may result in unconjugated
hyperbilirubinemia [5].
In our previous study, we found that the UGT1A1
211G > A mutation is associated with neonatal
hyperbilirubinemia in Asians [6]. Recently, studies have
suggested that variations of 388 G > A, 521 T > C, 463
C > A of the SLCO1B1 gene may predispose subjects toThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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uptake [7]. A high prevalence of 388 G > A (73.4%) and
521 T > C (14.0%) variants occurring in Chinese subjects
[8]. A 16% prevalence of 463 C > A variants has
been reported in Europeans and Americans, but this
variant appear to be of low prevalence in the Chinese
population [9]. Moreover, neonatal hyperbilirubinemia is
known to occur more frequently and to be more severe
in Asians than in Caucasians [10]. We hypothesized that
the SLCO1B1 mutation may be one of the risk factors
for neonatal hyperbilirubinemia, which possibly accounts
for the variability in prevalence rates in the Chinese neo-
nates. Therefore, we conducted a case-control study of
three variants (388 G > A, 521 T > C, 463 C > A) of
SLCO1B1 and investigated their association with neo-
natal hyperbilirubinemia in the Chinese neonates.Methods
Patients and controls
The subjects were term newborn infants, with a gesta-
tional age of more than 37 weeks, who were born
between August 2011 and January 2012 at the Fifth
People’s Hospital of Shenzhen, China. We excluded new-
born infants who were birth asphyxia, polycythemia,
hypothermia, hypoglycemia, cephalohematoma, hypo-
thyroidism, glucose-6-phosphate dehydrogenase (G-6-
PD) deficiency, or hemolytic disease of ABO and Rh
incompatibilities. We also excluded newborn infants
whose mothers were maternal diabetes, hypertension in
pregnancy, intrauterine infection.
Neonatal hyperbilirubinemia was defined as neonates
with total serum bilirubin levels exceeding the 95th
percentile, according to the Bhutani nomogram [11].
Total serum bilirubin levels were monitored and the
causes of neonatal hyperbilirubinemia were investigated
and treated following the 2004 American Academy of
Pediatrics (AAP) guidelines. The control group consis-
ted of neonates with total serum bilirubin levels below
the 40th percentile as defined by the Bhutani nomo-
gram [11]. The case-control study included a total of
183 infants with hyperbilirubinemia and 192 control
subjects.Table 1 Natural or mutagenesis primers, restriction enzymes,
Positions (cDNA) Primers Sequences
388 388 F 5′ATAATGGTGCAAATAA
G→ A 388R 5′ACTATCTCAGGTGATG
521 521 F 5′TTGTCAAAGTTTGCAA
T→ C 521R 5′GAAGCATATTACCCA
463 463 F 5′ATAATGGTGCAAATAA
C→ A 463R 5′ACCTTTTCCCACTATCMolecular analysis
The polymerase chain reaction–restriction fragment
length polymorphism (PCR-RFLP) method was applied
to detect three known variant sites (nucleotides 388, 463
and 521) of the SLCO1B1 gene. The natural or muta-
genic primers, restriction enzymes, and digested restric-
tion fragment sizes of the five known variants are listed
in Table 1. The PCR mixture (20 μL) consisted of 200 ng
of DNA, 20 ng of each primer, 1.25 mM of each dNTP
(3.2 μL), buffer solution (100 mM Tris HCl, 500 mM KCl,
15 mM MgCl2, and 0.01% gelatin), and 0.4 U of Taq DNA
polymerase. The PCR amplification was carried out in a
thermal cycler for 35 cycles of denaturation for 1 min at
94°C, annealing for 1 min at 55°C, primer extension for
1 min at 72°C, and a final extension for 10 min at 72°C.
The PCR product was digested with the appropriate re-
striction enzyme and analyzed on a 3% agarose gel.
Statistical analysis
We analyzed the collected data using Stata software
(version 9.0; Stata Corp. LP, College Station, TX, USA).
Genotype results were analyzed as the hyperbilirubi-
nemic group versus the control group. Allele frequencies
of genes were determined by calculating the percentage
of variant genes within the total number in the study
population. Comparisons between the study group and
the control group were performed with chi-square test
and Fisher’s exact test when expected values were <5%.
Results are given as relative risk (RR) with 95% confi-
dence intervals (CI).
Ethical considerations
The Ethics Committee on Human Experimentation of the
Faculty of Medicine, Fifth People’s Hospital of Shenzhen,
China, approved the study protocol. Informed consent
was obtained from the parents of each study infant.
Results
A total of 375 neonates were enrolled into the study.
Newborns with G6PD deficiency were not found in the
study group. The demographic and clinical data of the
hyperbilirubinemic group and the control group is sum-
marized in Table 2. There were no statistically significantand SLCO1B1 genes and variations
Restriction enzymes Results (bp)
AGGGG3′ Taq I G 128 + 63 + 23
CTCTA3′ A 151 + 63
AGTG3′ Hha I T 209
TGAGC3′ C 189 + 20
AGGGG3′ Hpa II C 205 + 19
TCCG3′ A 224
Table 2 Demographic and clinical data of newborn
infants enrolled into the study
Data Hyperbilirubinemia






38.35 ± 1.76 38.12 ± 1.53 0.18
Birth weight (g) 3238.32 ± 409.37 3194.53 ± 399.61 0.29
Sex: male 98 (53.55%) 102 (53.12%) 0.98
Delivery:
Normal 118 (64.48%) 121 (63.02) 0.85
Cesarean section 45 (24.59%) 49 (25.52%) 0.93
Forceps and vacuum
extraction
20 (10.93%) 22 (11.46%) 0.99
Feeding:
Breast milk only 46 (25.14%) 54 (28.13%) 0.59
Formula mixed
with breast milk
94 (51.37%) 97 (50.52%) 0.95
Formula only 43 (23.49%) 41 (21.35%) 0.71
Excessive weight loss
(>3% per day or ≥10%
of birth weight)
112 (61.2%) 119 (61.98%) 0.96
Liu et al. Italian Journal of Pediatrics 2013, 39:49 Page 3 of 5
http://www.ijponline.net/content/39/1/49differences in gestational age, birth weight, sex, delivery,
feeding between the two groups.
Analysis of SLCO1B1 at nt 388 revealed that 76 of the
183 (41.53%) neonates in the hyperbilirubinemic group
demonstrated the transition mutation (17 homozygous
and 59 heterozygous) compared to 53 of 192 (27.60%) in
the control group (10 homozygous and 43 heterozy-
gous). There were significant differences between geno-
type distributions of the SLCO1B1 388 G > A mutation
(Table 3). The risk of neonatal hyperbilirubinemia was
higher in SLCO1B1 388 G > A allele carriers (A/A + G⁄A)
than in G⁄G allele carriers (RR, 1.50; 95% CI, 1.13–2.00).
The allele frequency of the variant SLCO1B1 at nt 388
in infants in the hyperbilirubinemic group was 0.254,
which was significantly higher than that observed in the
control group (0.164, p = 0.003; Table 3). The likelihood
of developing neonatal hyperbilirubinemia was 1.55
times higher in infants with the A allele in SLCO1B1
388 G > A than in infants with the G allele (95% CI,
1.16–2.06).Table 3 Distributions of SLCO1B1 genotypes and allele frequ
Variants of genes Group Homozygous wild type Heterozyg
SLCO1B1 Case 107 59
nt 388 Control 139 43
SLCO1B1 Case 137 35
nt 521 Control 141 42
SLCO1B1 Case 183 0
nt 463 Control 192 0Analysis of the variant of SLCO1B1 gene at nt 521
revealed an allele frequency of 46 of 183 (25.14%) in
neonates in the hyperbilirubinemic group (11 homozy-
gous and 35 heterozygous), compared to 51 of 192
(26.56%) in the control group (9 homozygous and 42
heterozygous). There were no statistically significant
differences in the risk of neonatal hyperbilirubinemia
between SLCO1B1 521 T > C allele carriers (C/C + C/T)
and T⁄T allele carriers (RR, 0.95; 95% CI, 0.67–1.34).
The allele frequency of the variant SLCO1B1 at nt 521
in infants in the hyperbilirubinemic group was 0.156,
compared with 0.155 in the control group (Table 3).
There were no statistically significant differences in the
risk of neonatal hyperbilirubinemia between those with
the T allele in SLCO1B1 521 T > C and those with the C
allele (RR, 1.00; 95% CI, 0.72–1.40). No carriage of the C
to A substitution at nucleotide 463 was detected (Table 3).
Discussion
Various factors are involved in the development of
neonatal hyperbilirubinemia, including the SLCO1B1
gene, which requires further investigation as SLCO1B1
encodes a liver-specific member of the organic anion
transporter family. The encoded protein is a transmem-
brane receptor that can rapidly and selectively uptake
bilirubin into hepatocytes [12]. Variations within the
coding region of the SLCO1B1 gene may result in dys-
function of SLCO1B1 due to abnormal structure [13]. In
adult liver disease, polymorphism in the gene encoding
this protein is a major determinant of serum bilirubin
levels [14]. These findings indicate that variations in the
SLCO1B1 gene are possibly associated with neonatal
hyperbilirubinemia. The most frequent mutations of
SLCO1B1 in the Chinese population are the 388 G > A
mutation and the 521 T > C mutation [15]. The preva-
lence of 463 C > A variants of SLCO1B1 gene is low in
Chinese, but high in Europeans and Americans [16].
Neonatal hyperbilirubinemia is more frequent and more
severe in Chinese than in Europeans and Americans
[17], and the SLCO1B1 mutation may explain the vari-
ability in the prevalence of neonatal hyperbilirubinemia
among different ethnic groups.
Our study revealed that the 388 G > A mutation
of the SLCO1B1 gene is associated with neonatalencies with variants at nucleotide 388, 521 and 463
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the frequency of the G allele in the 388 G > A mutation
in hyperbilirubinemic and in control infants (0.254 and
0.164, respectively) revealed significant differences. The
likelihood of developing neonatal hyperbilirubinemia
was 1.55 times higher in 388 G > A mutants with the A
allele than in those with the G allele. The allele fre-
quency of the variant SLCO1B1 at nt 521 in infants in
the hyperbilirubinemic group did not demonstrate a sta-
tistically significant difference compared with the control
group (0.156 and 0.155, respectively). No carriage of the
C to A substitution at nucleotide 463 of the SLCO1B1
gene was detected. The results of our case-control study
were consistent with those of a previous study involving
the Chinese neonates, which is conflicting with the study
from Brazil [18]. The allele frequency of SLCO1B1
(388A > G) in chinese populations was 63.5% [19],
which was higher than Brazilians (white was 50.4% and
black was 35.1%) [20]. The genetics of racial differences
might explain the different association between the
genetic polymorphism of SLCO1B1 and neonatal hyper-
bilirubinemia among different ethnic groups.
In genetic epidemiology, a genome-wide association
study (GWAS) examines all or most of the genes of dif-
ferent variations associated with different diseases. It is
more powerful than a case-control study for single gen-
etic polymorphisms. Recently, one GWAS based on
European adult populations suggested that genetic varia-
tions of SLCO1B1 influence bilirubin levels [21]. An-
other cohort from the Mayo Genome Consortia also
showed that genetic variants of SLCO1B1 were associ-
ated with total bilirubin levels in Americans [22].
However, both a GWAS based on European adult popu-
lations [23] and a large-scale GWAS based on Korean
adults [24] contradicted these results, suggesting that
genetic variations of SLCO1B3 influence bilirubin levels,
not SLCO1B1. The SLCO1B3 gene is also a member of
the OATP family, which is highly expressed in the
basolateral membrane of hepatocytes. SLCO1B3 and
SLCO1B1 share 80% amino acid sequence identity and
have similar substrate selectivity [25]. Functionality
between these two human transporters in the OATP
family can be distinguished using estrone-3-sulfate, a
SLCO1B1-selective ligand, and cholecystokinin octapep-
tide, a SLCO1B3-selective ligand [26]. Whether SLCO
1B3 and SLCO1B1 are associated with bilirubin levels or
differentially contribute in a population-specific fashion,
needs further investigation.
Conclusions
The cohort study which analyzed the genetic association
was time-consuming, laborious, and high costly, so,
there was still not one prospective cohort study which
assessed genetic variations associated with hyperbiliru-binemia. Our case-control study found that the variant
SLCO1B1 388 G > A is associated with neonatal
hyperbilirubinemia in Chinese neonates; further pro-
spective cohort study is need to conform the association.
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